Savara price target raised to $8 from $5 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Savara (SVRA) to $8 from $5 and keeps a Buy rating on the shares after the company announced that the Autoimmune Pulmonary Alveolar Proteinosis patient population in the U.S. is an estimated 50% greater than the company originally estimated based on an updated health claims record analysis using more recent and comprehensive records. Savara initially identified the patient population of 3,600 confirmed aPAP patients, notes the analyst, who believes that the increase in confirmed aPAP patients to 5,500 “helps to dissuade concerns regarding the initial market for Molbreevi upon anticipated launch.”